Romain Villéger | Host-bacteria interactions | Cell Metabolism Award

Published on by Cell Biologist

Assist. Prof. Dr. Romain Villéger | Host-bacteria interactions | Cell Metabolism Award

Assist. Prof. Dr. Romain Villéger , Université de Poitiers , France

Dr. Romain Villéger is an Assistant Professor at the University of Poitiers, France, in the Ecology & Biology of Interactions (EBI) lab, within the Microorganisms-Hosts-Environments (MHE) team. With a Ph.D. from the University of Limoges, his work explores the intricate interactions between probiotics and host cells. He has held postdoctoral positions at the University of Bordeaux and the University of Texas Medical Branch, USA, focusing on microbiota-host relationships and metabolomics. Dr. Villéger’s research aims to unravel the role of bacterial interactions, particularly in the context of gastrointestinal health, microbiota, and cancer. His research has led to significant advancements in understanding microbial pathogenesis, including the effects of probiotics and endocrine disruptors on host cell metabolism. A dedicated researcher, he has contributed to numerous scientific publications and currently leads several high-impact projects on bacteria-host interactions.

Publication Profile:

Scopus

Strengths for the Award:

  1. Expertise in Metabolomics: Dr. Romain Villéger’s extensive work in metabolomics, especially in the context of host-bacteria interactions, positions him as a strong candidate for the Cell Metabolism Award. His research on bacterial influence on host cellular metabolism and gut microbiota interactions contributes significantly to the field of cellular metabolism.
  2. Innovative Research Contributions: His research, particularly on the metabolic changes during amoeba-Legionella interactions, showcases a novel approach to understanding microbial pathogenesis. By identifying metabolic vulnerabilities in pathogens, his work has the potential for therapeutic applications, thus addressing fundamental questions in cell metabolism.
  3. Multidisciplinary Approach: Dr. Villéger combines microbiology, immunology, and metabolomics, which enriches his contributions to cellular metabolism. His research is collaborative, evidenced by numerous projects across different institutions and fields, indicating a broad and innovative approach to the subject.
  4. Publications and Impact: He has a strong publication record, with numerous articles in peer-reviewed journals (19 publications), with high visibility in top-tier journals such as British Journal of Cancer, Frontiers in Cellular and Infection Microbiology, and Environmental Microbiology Reports. This demonstrates his influence and impact in the scientific community.
  5. Research Leadership: As the principal investigator of multiple projects, including those on the effects of phthalates on gut microbiota and cancer development, Dr. Villéger has demonstrated leadership in advancing scientific knowledge in areas that intersect with cell metabolism, host-microbe interactions, and metabolic changes in disease.

Areas for Improvement:

  1. Broader Clinical Translation: While his research shows deep insights into fundamental mechanisms, further work on translating these findings into practical clinical applications or therapeutic interventions would strengthen his impact in applied cellular metabolism.
  2. Interdisciplinary Team Development: While Dr. Villéger collaborates with many renowned researchers, fostering additional interdisciplinary partnerships could enrich his research by incorporating diverse techniques and perspectives from fields like drug development or personalized medicine.
  3. Expanding Metabolomic Toolkits: His research could benefit from exploring emerging and cutting-edge techniques in metabolomics, like single-cell analysis or multi-omics approaches, to gain deeper insights into cellular metabolism at the individual cell level.

Education:

Dr. Villéger completed his Ph.D. at the University of Limoges, where his thesis focused on the interactions between probiotics and host cells. His postdoctoral work spans institutions in France, the USA, and beyond, each contributing valuable insights into microbial-host dynamics and cellular microbiology. At the University of Bordeaux, he developed metabolomic approaches using GC/MS to study microbiota interactions. Later, at the University of Texas Medical Branch, he delved deeper into the effects of probiotics on intestinal homeostasis. Further postdoctoral experiences at the University of Clermont Auvergne involved examining the relationship between E. coli and colorectal cancer. Through these experiences, Dr. Villéger has gained expertise in microbiota research, cell biology, and metabolic analysis, providing a foundation for his ongoing work in the field. His education has provided a strong interdisciplinary framework, integrating microbiology, molecular biology, and toxicology into his research.

Experience:

Dr. Villéger has accumulated extensive experience in both academic and research settings. After earning his Ph.D. in 2014, he completed several postdoctoral positions, with notable work at the University of Bordeaux, where he pioneered metabolomics techniques for microbiota research. His tenure at the University of Texas Medical Branch expanded his focus to the effects of probiotics on intestinal homeostasis. Additionally, his work at the University of Clermont Auvergne involved exploring the connection between microbial interactions and cancer. Since joining the University of Poitiers in 2020 as an Assistant Professor, Dr. Villéger has led several research projects, including investigating the impact of endocrine disruptors on colorectal cancer development. He is also a leader in metabolomics and microbial pathogenesis, with a particular focus on bacteria-host interactions and microbiota modulation. His research has contributed to numerous publications and collaborations with institutions worldwide, showcasing his ability to manage complex research projects.

Research Focus:

Dr. Villéger’s research primarily focuses on bacteria-host interactions, gut microbiota, and cellular microbiology, with a special interest in how microbial populations affect host metabolism. His work integrates metabolomics, a powerful tool for studying metabolic processes, to better understand microbial influence on host cells. Dr. Villéger’s recent studies explore the role of oxidative stress in microbial infections, including Legionella pneumophila’s subversion of host immune defenses during infection. He has also investigated the impact of endocrine disruptors on microbial virulence, providing insights into the potential links between environmental factors and microbial pathogenesis. His contributions to understanding the microbiota-gut-brain axis, particularly in the context of colorectal cancer, emphasize the metabolic changes induced by bacterial interactions. Dr. Villéger’s research aims to identify biomarkers for disease and therapeutic interventions, with a broader goal of advancing precision medicine through a better understanding of the cellular and metabolic processes that underlie microbial-host dynamics.

Publications Top Notes:

  1. Legionella pneumophila subverts the antioxidant defenses of its amoeba host Acanthamoeba castellanii 💥🦠
  2. Increased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn’s Disease 🔬🧬
  3. Exposure to endocrine disruptors promotes biofilm formation and contributes to increased virulence of Pseudomonas aeruginosa 💧🦠
  4. Loss of alcohol dehydrogenase 1B in cancer-associated fibroblasts: contribution to the increase of tumor-promoting IL-6 in colon cancer 🧬🦠
  5. Effect of endocrine disruptors on bacterial virulence 🌿🧪
  6. Proteomic analysis of Acanthamoeba castellanii response to Legionella pneumophila infection 🔬🦠
  7. Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism 🧬🍊
  8. Microbiota medicine: towards clinical revolution 🌍💊
  9. Deletion of cystathionine-γ-lyase in bone marrow-derived cells promotes colitis-associated carcinogenesis 🔬🦠
  10. Prebiotic Isomaltooligosaccharide Provides an Advantageous Fitness to the Probiotic Bacillus subtilis CU1 🍞🦠

Conclusion:

Dr. Romain Villéger is a highly qualified candidate for the Cell Metabolism Award. His research contributions in understanding microbial influence on cellular metabolism and gut health, combined with his innovative approach to metabolomics, make him stand out in the field. His work bridges basic science and potential clinical applications, positioning him as a key figure in the ongoing exploration of microbial and metabolic influences on host physiology. With some expansion into clinical applications and further exploration of new metabolomics techniques, his contributions could significantly impact both scientific knowledge and medical practice.

 

 

 

Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Prof. Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China

Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.

Publication Profile:

Scopus

Strengths for the Award:

  1. Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
  2. Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
  3. Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
  4. Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.

Areas for Improvement:

  1. Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
  2. Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
  3. Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.

Education:

Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.

Experience:

Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.

Research Focus:

Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.

Publications Top Notes:

  • The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
  • Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
  • Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
  • Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
  • Extracellular Vesicle‐Based Nanodrug Delivery 💊
  • Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
  • Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
  • Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
  • Smart delivery of poly-peptide composite for effective cancer therapy 💡
  • The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️

Conclusion:

Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.

 

 

 

Huiying Fan | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Huiying Fan | Host-Pathogen Interactions | Best Researcher Award

Dr. Huiying Fan , College of Veterinary Medicine, South China Agricultural University , China

Dr. Huiying Fan is a distinguished professor and doctoral supervisor at the College of Veterinary Medicine, South China Agricultural University, specializing in veterinary virology and immunology. As a core member of the Key Laboratory for Veterinary Vaccine Development, his expertise includes creating genetically engineered vaccines for animal viruses. Dr. Fan has published over 40 research papers in leading journals, including Journal of Virology and Emerging Microbes & Infections, and holds 11 invention patents. His career has been marked by significant contributions to animal virus research and vaccine development, with extensive involvement in national research programs. He has been recognized with several provincial and ministerial-level awards and is actively involved in scientific development and industry collaboration in China.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huiying Fan has demonstrated exceptional contributions to the field of veterinary virology and immunology, particularly in the development of vaccines for animal viruses. He is a recognized leader in the creation of genetically engineered vaccines, with over 40 SCI papers published in high-impact journals such as Journal of Virology, Emerging Microbes & Infection, and Vaccines. His involvement in groundbreaking research on the pathogenic mechanisms of viruses like avian influenza, porcine epidemic diarrhea, and African swine fever underscores his expertise. Furthermore, Dr. Fan has been granted 11 invention patents and is an influential figure in national research programs, such as the National Key Research and Development Program. His leadership as a professor and mentor, coupled with his ongoing innovations in virus detection and vaccine development, showcases his remarkable impact in the field.

Areas for Improvement:

While Dr. Fan’s scientific research has been groundbreaking, expanding his focus on broader global collaborations could enhance the scope of his work. In particular, his work could benefit from incorporating more interdisciplinary approaches, combining cutting-edge technologies such as artificial intelligence or big data analytics, which are becoming increasingly crucial in disease surveillance and vaccine development. Moreover, his research could further address the application of his vaccine technologies in low-resource settings, to maximize global health impact. Engaging more actively in science communication could also help translate his findings into policies or programs that benefit larger populations, both within China and internationally.

Education:

Dr. Fan completed his Ph.D. in Preventive Veterinary Medicine at the College of Veterinary Medicine, Huazhong Agricultural University, in June 2007. During his doctoral research, he focused on the study of veterinary diseases and virus-host interactions, laying a strong foundation for his future work in vaccine development. His commitment to advancing veterinary science continued through postdoctoral training, followed by his establishment as a professor at South China Agricultural University. His education reflects his dedication to merging academic research with practical applications for the improvement of animal health and disease prevention.

Experience:

Dr. Fan’s career began in 2007 as a professor at South China Agricultural University, where he became a leading figure in veterinary medicine. He has also contributed significantly to international research, evidenced by his six-month research visit to City University of Hong Kong in 2016. As a core member of several high-impact research initiatives, including the National Key Research and Development Program, he has played a vital role in advancing veterinary virology and vaccine development. Dr. Fan’s extensive expertise has led to collaborations across national projects and scientific endeavors, particularly in the realm of infectious diseases and immune responses in animals.

Awards and Honors:

Dr. Fan has received multiple prestigious awards throughout his career, including 8 provincial and ministerial-level honors. Notably, he was named a “Pearl River Science and Technology Star” in Guangzhou and recognized as a “Science and Technology Commissioner” by the People’s Government of Guangdong Province. His contributions to veterinary science have garnered recognition both within China and internationally, highlighting his commitment to scientific excellence and industry collaboration. These accolades underscore his leadership in veterinary vaccine research and his influence on public health initiatives concerning animal diseases.

Research Focus:

Dr. Fan’s primary research interests lie in the molecular design of genetically engineered vaccines for animal viruses, including those affecting poultry and swine. His studies explore the immune mechanisms and pathogenesis of viruses such as avian influenza and porcine viral diarrhea. In addition to his work on vaccine development, he investigates the use of innovative techniques, including CRISPR/Cas12a and proteomics, to better understand virus-host interactions and to improve diagnostic and therapeutic strategies for animal diseases. His focus on veterinary virology aims to enhance both animal and public health outcomes.

Publication Top Notes:

  1. “A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses” 🐔🦠
  2. “Influenza H7N9 Virus Hemagglutinin with T169A Mutation Possesses Enhanced Thermostability” 🦠❄️
  3. “Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus” 🐖🦠
  4. “Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection” 🦠💉
  5. “PEDV infection affects the expression of polyamine-related genes inhibiting viral proliferation” 🐖🧬
  6. “Proteome Analysis in PAM Cells Reveals That African Swine Fever Virus Can Regulate Intracellular Polyamines” 🧬🔬
  7. “CRISPR/Cas12a Technology Combined with Immunochromatographic Strips for Portable Detection of ASF Virus” 🧬🦠
  8. “Quantitative Proteomics Reveals Changes in Vero Cells in Response to Porcine Epidemic Diarrhea Virus” 🐖🔬
  9. “Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of H5N1 vaccine” 💉🦠
  10. “Either fadD1 or fadD2, Which Encode acyl-CoA Synthetase, Is Essential for the Survival of Haemophilus parasuis SC096” 🦠🔬
  11. “Two Glycosyltransferase Genes of Haemophilus parasuis SC096 Implicated in Lipooligosaccharide Biosynthesis” 🧬🦠
  12. “Recombinant baculovirus vaccine containing multiple M2e and adjuvant LT induces T cell-dependent protection against H5N1” 💉🦠
  13. “BacMam virus-based surface display of IBV S1 glycoprotein confers strong protection against virulent IBV challenge” 🐔🦠
  14. “Quantitative Proteomics by Amino Acid Labeling in Foot-and-Mouth Disease Virus-Infected Cells” 🐄🧬
  15. “Quantitative proteomics using SILAC reveals protein and pathway regulation in porcine circovirus type 2 infected PK-15 cells” 🐖🧬

Conclusion:

Dr. Huiying Fan is undoubtedly a strong contender for the Research for Best Researcher Award, given his outstanding contributions to animal virus research, innovative vaccine design, and leadership in national research initiatives. His extensive publication record, patent portfolio, and recognition through prestigious awards highlight his scientific excellence. Although expanding his collaborative network and exploring interdisciplinary methodologies could elevate his impact further, Dr. Fan’s work has already had a profound effect on veterinary medicine and public health, making him a well-deserved nominee for this award.